Choline glycerophosphate CAS#: 28319-77-9; 凯望编码 (ChemWhat Code): 285551
Identification
| 英文名 | Choline glycerophosphate |
| IUPAC Name | [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate |
| 分子结构 |  |
| CAS编号 | 28319-77-9 |
| EINECS Number | 248-962-2 |
| MDL Number | MFCD00063544 |
| Beilstein Registry Number | No data available |
| 别名 | L-α-Glycerylphosphorylcholine (2R)-2,3-Dihydroxypropyl 2-(trimethylammonio)ethyl phosphate [ACD/IUPAC Name] (2R)-2,3-Dihydroxypropyl-2-(trimethylammonio)ethylphosphat [German] [ACD/IUPAC Name] (R)-2-[[(2,3-Dihydroxypropoxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium hydroxide inner salt CAS# 28319-77-9 CAS No: 28319-77-9 |
| 分子式 | C8H20NO6P |
| 分子量 | 257.22 |
| InChI | InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1 |
| InChI Key | SUHOQUVVVLNYQR-MRVPVSSYSA-N |
| Canonical SMILES | CN+(C)CCOP(=O)([O-])OCC@@HO |
| Patent Information |
| No data available |
Physical Data
| Appearance | White powder |
| Flash Point | 11°C |
| Melting Point, °C | Solvent (Melting Point) | Comment (Melting Point) |
| 145 – 147 | ethanol, isopropyl alcohol | |
| 142.5 – 143 | ethanol | kryst. bei -15grad. |
| Density, g·cm-3 | Type (Density) |
| 1.32 | crystallographic |
Spectra
| Description (NMR Spectroscopy) | Nucleus (NMR Spectroscopy) | Solvents (NMR Spectroscopy) | Temperature (NMR Spectroscopy), °C | Frequency (NMR Spectroscopy), MHz |
| Spectrum | 1H | 5.84 | ||
| Chemical shifts, Spectrum | 1H | 25 | 700 | |
| Chemical shifts | 1H | dimethylsulfoxide-d6 | ||
| Chemical shifts | 31P | water-d2 | 161.9 | |
| Chemical shifts | 1H | water-d2 | 24.84 | 400.1 |
| Linewidth of NMR absorption | 31P | chloroform-d1 | 26.84 | 162 |
| Chemical shifts | 1H | H2O, NaCl | 37 | 400 |
| Spectrum | 1H | 37 | 400 | |
| Chemical shifts | 1H | D2O, various solvent(s) | ||
| Chemical shifts | 13C | CDCl3, tetradeuteriomethanol | 36 – 38 | |
| Spin-spin coupling constants | CDCl3, tetradeuteriomethanol | 36 – 38 | ||
| Chemical shifts | 14N | D2O |
| Description (IR Spectroscopy) | Solvent (IR Spectroscopy) | Comment (IR Spectroscopy) |
| Spectrum | KBr | 5000 – 667 cm**(-1) |
| Spectrum | nujol | 5000 – 667 cm**(-1) |
| Description (Mass Spectrometry) |
| liquid chromatography mass spectrometry (LCMS), time-of-flight mass spectra (TOFMS), electrospray ionisation (ESI), spectrum |
| time-of-flight mass spectra (TOFMS), electrospray ionisation (ESI), spectrum |
| IT (ion trap), liquid chromatography mass spectrometry (LCMS), electrospray ionisation (ESI), spectrum |
| time-of-flight mass spectra (TOFMS), electrospray ionisation (ESI), spectrum |
| liquid chromatography mass spectrometry (LCMS), high resolution mass spectrometry (HRMS), time-of-flight mass spectra (TOFMS), tandem mass spectrometry, electrospray ionisation (ESI), spectrum |
| liquid chromatography mass spectrometry (LCMS), spectrum |
| electrospray ionisation (ESI), spectrum |
Route of Synthesis (ROS)
| Conditions | Yield |
| Stage #1: L-glycero-3-phosphorylcholine With di(n-butyl)tin oxide In isopropyl alcohol for 1h; Heating; Stage #2: n-hexadecanoyl chloride With TEA In isopropyl alcohol at 25℃; for 0.25h; Further stages.; | 97% |
| Stage #1: L-glycero-3-phosphorylcholine With di(n-butyl)tin oxide In isopropyl alcohol for 1h; Reflux; Stage #2: n-hexadecanoyl chloride With triethylamine at 20℃; for 1h; | 90% |
| Stage #1: L-glycero-3-phosphorylcholine With di(n-butyl)tin oxide In isopropyl alcohol for 1h; Heating; Stage #2: n-hexadecanoyl chloride With TEA In isopropyl alcohol at 25℃; for 0.25h; Further stages.; | 80% |
| Stage #1: L-glycero-3-phosphorylcholine With di(n-butyl)tin oxide In isopropyl alcohol for 1h; Reflux; Stage #2: n-hexadecanoyl chloride With triethylamine In isopropyl alcohol at 25℃; for 0.25h; | 80% |
| Stage #1: L-glycero-3-phosphorylcholine With di(n-butyl)tin oxide In isopropyl alcohol at 100℃; for 1h; Stage #2: n-hexadecanoyl chloride With triethylamine In isopropyl alcohol at 20℃; Experimental Procedure 1-O-Hexadecanoyl-sn-glycero-3-phosphocholine (7) General procedure: This compound was prepared as in the literature with some modifications.4 NMR spectra of this compound and of regioisomers can be found elsewhere.5 Migration in compound 7 has been reported when silica gel chromatography was used for purification,6 and sufficient isomeric purity was concluded from 1H- and 13C-NMR in our synthetic protocol. A 100 mL one-neck round-bottom flask equipped with a reflux condenser, was consecutively charged with 2.00 g (8.3 mmol, 1 eq) GPC (6), 2.20 g (8.83 mmol, 1.1 eq) dibutyltin oxide and 80 mL iPrOH. The flask was placed in a pre-heated oil-bath (~100 °C) and it was stirred for 1 h at this temperature. It was cooled to rt, after which 1.3 mL (9.38 mmol, 1.1 eq) Et3N and 2.8 mL (9.2 mmol, 1.1 eq) palmitoyl chloride were added and it was stirred at rt overnight. Subsequently, the mixture was transferred into a separation funnel containing 80 mL H2O and the aqueous layer was washed with pentane (3×80 mL). The aqueous layer was then concentrated in vacuo and the crude product was purified via flash column chromatography (19 g SiO2 gel, 11.8×2.3 cm, 15 mL frac., frac. 6-27 pooled). Yield= 1.28 g (2.58 mmol, 31 %), colorless solid C24H50NO7P [495.63 g·mol-1] Rf= 0.25 (CH2Cl2/MeOH/H2O= 65/25/4, KMnO4) 1H-NMR (300 MHz, MeOD-d4): δ= 4.36-4.24 (m, 2H), 4.24-3.84 (m, 5H), 3.72-3.62 (m, 2H), 3.22 (s, 9H), 2.36 (t, J= 7.5 Hz, 2H), 1.71-1.53 (m, 2H), 1.43-1.19 (m, 24H), 0.90 (t, J= 6.7 Hz, 3H). 13C-NMR (75 MHz, MeOD-d4): δ= 175.3, 69.7, 67.9, 67.5, 66.2, 60.5, 54.7, 34.9, 33.1, 31.0-30.0 (m), 26.0, 23.7, 14.5. Missing signals due to overlap. | 31% |
Safety and Hazards
| GHS Hazard Statements | Not Classified For more detailed information, please visit ECHA C&L website |
| Source: European Chemicals Agency (ECHA) License Note: Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: “Source: European Chemicals Agency, http://echa.europa.eu/”. Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page. License URL: https://echa.europa.eu/web/guest/legal-notice Record Name: (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate URL: https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/213446 Description: The information provided here is aggregated from the “Notified classification and labelling” from ECHA’s C&L Inventory. Read more: https://echa.europa.eu/information-on-chemicals/cl-inventory-database |
Other Data
| Transportation | Under the room temperature and away from light |
| HS Code | 296200 |
| Storage | Under the room temperature and away from light |
| Shelf Life | 1 year |
| Market Price | USD |
| Druglikeness | |
| Lipinski rules component | |
| 分子量 | 257.224 |
| logP | -2.928 |
| HBA | 6 |
| HBD | 2 |
| Matching Lipinski Rules | 4 |
| Veber rules component | |
| Polar Surface Area (PSA) | 108.86 |
| Rotatable Bond (RotB) | 8 |
| Matching Veber Rules | 2 |
| Bioactivity |
| In vitro: Efficacy |
| Quantitative Results |
| pX | Parameter | Value (qual) | Value (quant) | Unit | Target | Dose | Effect |
| 6 | Protection rate | Active | 8.05 | 1 – 10 μM | cardioprotective agent | ||
| 4.1 | Protection rate | Active | 80 μM | cardioprotective agent | |||
| 4 | Protection rate | Active | 100 μM | cardioprotective agent | |||
| 1 | Percentage change(ROS level) | Not active | 1 – 100 μM | cardioprotective agent | |||
| 1 | Percentage change(superoxide anion produced) | Not active | 1 – 100 μM | cardioprotective agent | |||
| percentage(Relative uptake) | = | 73.2 | % | Solute carrier family 22 member 1 [human]:Wild | = 1 mM | ||
| Activity(relative activity) | < | 1 | % | Galactose-3-O-Sulfotransferase [pig]:Wild |
| Quantitative Results | ||
| 1 of 10 | Biological material | macrophage |
| Assay Description | Effect : metabolic Bioassay : LPS: lipopolysaccharide in vitro; effect on NO production assayed; cells from mice fed normal diet for 2 weeks; incub. with title comp. prior to stimulation with Escherichia coli LPS for 24 h; NO production assessed by formation of nitrite measurements | |
| 2 of 10 | Effect | vasoconstrictor agent |
| Assay Description | Target : arteries from Wistar rat Bioassay : isometric tension (IT) stimulated with 1 μM ; IT measured in physiological salt solution (O2:CO2=95:5; pH 7.45-7.50); title comp. effect on stimulated IT studied rings from mesenteric bed of 12-16-w-old male rats mounted in myograph without/with endothelium (-/+E); α-toxin permeabilized by reported method ; title comp. added to bath |
| Toxicity/Safety Pharmacology |
| Quantitative Results |
| pX | Parameter | Value (qual) | Value (quant) | Unit | Target | Effect |
| 6 | increase rate(superoxide anion produced) | Active | Cytotoxic | |||
| 6 | increase rate(ROS level) | Active | Cytotoxic | |||
| 4.67 | IC50 | 21.2 | μM | Phosphoserine phosphatase (gene PSPH) [Caenorhabditis elegans]:Wild | Neurotoxic | |
| 1 | inhibition rate | Not active | ||||
| 1 | increase rate(ROS level) | Active | Cytotoxic | |||
| 1 | Decrease rate | Not active | ||||
| 1 | Percentage change(of cell viability) | Not active | Cytotoxic | |||
| LD50 | = | 650 | mg/kg | |||
| LD50(Lethal dose) | 13000 | mg/kg | ||||
| increase rate(Oxygen consumption rate) | High | Cytotoxic |
| Use Pattern |
| Choline glycerophosphate CAS#: 28319-77-9 is used as Pharmaceuticals |
| Choline glycerophosphate CAS#: 28319-77-9 is treating cognitive dysfunction associated with cerebrovascular diseases |
| Hamartomatous diseases |
| Choline glycerophosphate CAS#: 28319-77-9 Tuberous sclerosis |
| Pulmonary harnartoma |
| von Meyenburg complex |
| Birt-Hogg-Dube syndrome |
| Multiple hemartoma syndrome |
| antioxidant suitable for use in foods, feeds or cosmetics |
| improvement of environmental stress tolerance |
试剂采购 | |
| 没有试剂厂商? | 向凯望发送快速询价 |
| 想要被列为试剂厂商? (付费服务) | 点击这里联系凯望 |
认证生产商 | |
| Caming Pharmaceutical Ltd | http://www.caming.com/ |
| 想要被列为认证生产商 (需要通过认证)? | 请下载并填写 这份表格并发邮件到approved-manufacturers@chemwhat.com |
其他供应商 | |
| Watson International Limited | 访问Watson官网 |
如需其他帮助，请联系我们 | |
| 联系我们获取其它信息或服务 | 点击这里联系凯望 |